Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Systematic assessment of omega-3 fats on cardiovascular health suggests that increasing EPA and DHA has little or no effect on mortality or cardiovascular health (evidence mainly from supplement trials) putting into question previous suggestions of benefits from EPA and DHA supplements. Low-quality evidence suggests ALA may slightly reduce CVD event risk, CHD mortality and arrhythmia. Additional large studies of omega 3 are currently underway.
Related stories
- Lipoprotein (a) disorder gets SNOMED codes
- Would you like to update your knowledge of lipid management and have the opportunity to liaise with others working in this area?
- Familial Hypercholesterolaemia Gene Testing One-Day Online Workshop - Dates for 2023
- New SNOMED Codes for FH DNA test results!
- Healthcare Professional Dietary Survey Prize Draw 2022
- Opportunity to join the NICE CG181 guideline committee
- NICE launches review of methods and processes for health technology evaluation
- The Essential Cholesterol Programme for Primary Care
- Add on to take back control. Do we have the solutions to the gaps in our lipid treatment pathway?
- Familial Hypercholesterolaemia: from Epidemiology to Genetics – a paradigm shift?